Cochrane Review Group

Kidney and Transplant

139 systematic reviews in Kidney and Transplant ask 2,434 questions. 20.7% have no studies to answer them, 25.1% rest on very low certainty evidence and 20.1% reach moderate or high certainty.

Reviews

139

Questions

2,434

current versions

No studies

20.7%

Moderate or high

20.1%

No studies 504 · 20.7%Ungraded 40 · 1.6%Very low 611 · 25.1%Low 790 · 32.5%Moderate 414 · 17%High 75 · 3.1%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Search questions in Kidney and Transplant

Thinnest evidence

All no studies and very low questions

Question	Effect	Evidence	Status / GRADE
Valaciclovir vs ganciclovir or valganciclovir Acute rejection · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	RR 0.91 [0.22, 3.73]	3 studies · 271 participants	Very low
Low vs standard dose valganciclovir Opportunistic infection · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	no estimate extracted	NR	No studies
Low vs standard dose valganciclovir Adverse events · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	no estimate extracted	NR	No studies
Maribavir vs ganciclovir Graft loss · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	no estimate extracted	NR	No studies
Maribavir vs ganciclovir Opportunistic infection · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	no estimate extracted	NR	No studies
Renin‐angiotensin system inhibition vs placebo or no treatment Death (any cause) · people with IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	no estimate extracted	NR	No studies
Renin‐angiotensin system inhibition vs other supportive care treatment Remission of proteinuria · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	no estimate extracted	NR	No studies
Renin‐angiotensin system inhibition vs other supportive care treatment Remission of haematuria · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	no estimate extracted	NR	No studies
Renin‐angiotensin system inhibition vs other supportive care treatment Relapse of proteinuria · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	no estimate extracted	NR	No studies
Tonsillectomy plus standard care vs standard care Death (any cause) · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	no estimate extracted	NR	No studies
Tonsillectomy plus standard care vs standard care Kidney failure · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	no estimate extracted	NR	No studies
Tonsillectomy plus standard care vs standard care Relapse of haematuria (macroscopic) · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	RR 1.33 [0.8, 2.23]	1 study · 32 participants	Very low

Reviews 139

Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients

Vernooij, RWM, Michael, M, et al. · Cochrane Database of Systematic Reviews · 2024

Kidney and Transplant

Thinnest evidence

Reviews 139

Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients

Non‐immunosuppressive treatment for IgA nephropathy

Robotic versus laparoscopic versus open nephrectomy for live kidney donors

Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic kidney disease

Home versus in‐centre haemodialysis for people with kidney failure

Anticoagulation for people receiving long‐term haemodialysis

Interventions for thrombosed haemodialysis arteriovenous fistulas and grafts

Metformin for preventing the progression of chronic kidney disease

Interventions for preventing haemodialysis dysequilibrium syndrome

Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes

Cranberries for preventing urinary tract infections

Interventions for preventing and treating kidney disease in IgA vasculitis

Altered dietary salt intake for preventing diabetic kidney disease and its progression

Interventions for dialysis patients with hepatitis C virus (HCV) infection

Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non‐diabetic chronic kidney disease

HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis

Antioxidants for adults with chronic kidney disease

Catheter insertion techniques for improving catheter function and clinical outcomes in peritoneal dialysis patients

Interventions for fatigue in people with kidney failure requiring dialysis

Synbiotics, prebiotics and probiotics for people with chronic kidney disease

Early versus late removal of urinary catheter after kidney transplantation

Protein restriction for diabetic kidney disease

Interventions for minimal change disease in adults with nephrotic syndrome

Interventions for focal segmental glomerulosclerosis in adults

Antiplatelet agents for chronic kidney disease